A estratificação de risco para morte súbita em pacientes com cardiomiopatia hipertrófica ainda é um desafio. Sua prevenção pelo cardiodesfibrilador automático é eficaz, porém, onerosa e não isenta de riscos. Pacientes com indicação de cardiodesfibrilador automático para prevenção primária, baseada em fatores de risco clínicos, apresentam baixa taxa de terapias apropriadas. Estudos que validem novos fatores de risco são necessários, visando identificar pacientes com maior probabilidade de morte súbita e, portanto, que se beneficiam do implante do dispositivo. Estudos que correlacionam a presença de realce tardio com arritmias ventriculares e morte súbita foram realizados, entretanto, sua aplicabilidade clinica ainda não é consenso. Objetivos: Avaliar, em portadores de cardiomiopatia hipertrófica, se a presença e a extensão de realce tardio, identificado pela tomografia computadorizada, correlaciona-se com a ocorrência de taquiarritmias ventriculares registradas no monitor de eventos do cardiodesfibrilador automático, durante um seguimento clínico ambulatorial. Métodos: Foram incluídos pacientes com cardiomiopatia hipertrófica dos ambulatórios de Eletrofisiologia e Miocardiopatias do Instituto Dante Pazzanese de Cardiologia. Os pacientes foram divididos em dois grupos: grupo I composto por aqueles que receberam terapia apropriada pelo cardiodesfibrilador automático ou tiveram apenas a documentação de taquicardia ventricular não sustentada pelo cardiodesfibrilador automático; grupo II, composto por pacientes sem documentação de arritmias ventriculares no monitor de eventos. As variáveis contínuas foram comparadas utilizando-se testes t de Student pareado ou Wilcoxon; para as categóricas o teste do x2. Para análise dos dados, utilizou-se o programa SPSS. Valores de p < 0,05 foram considerados estatisticamente significativos. Resultados: Sessenta e um pacientes (idade média 39±15 anos, 51% mulheres, com seguimento médio 5,13±3,0 anos) foram avaliados. Em 91,8%, a indicação do cardiodesfibrilador automático foi por prevenção primária. Durante o seguimento clínico, cinco pacientes (8,2%) apresentaram terapias apropriadas e 15 (24,6%) tiveram taquicardia ventricular não sustentada, mas sem terapia. A densidade de fibrose (incluindo massa de ventrículo esquerdo acometida e percentual de acometimento) não foi estatisticamente diferente entre os grupos I e II (4,3±4,8% vs 7,0±7,7% nos grupos I e II, respectivamente, p = 0,13). Entretanto, 85% dos pacientes com taquicardia ventricular apresentavam fibrose à tomografia computadorizada. Maiores densidades de fibrose se correlacionaram com idades mais jovens, com menores frações de ejeção e sexo masculino. Espessura septal >= 30mm se correlacionou à maior massa de fibrose. Houve correlação entre o surgimento de fibrilação atrial e maior porcentual de fibrose do ventrículo esquerdo. Dentre os fatores que se correlacionaram com maior densidade de fibrose, nenhum deles se correlacionou com eventos arrítmicos ventriculares. A associação dos fatores clínicos ou fatores clínicos isolados que motivaram a indicação do implante do cardiodesfibrilador automático não se correlacionou com eventos arrítmicos. Os pacientes do grupo I apresentaram maior diâmetro diastólico do ventrículo esquerdo e maior diâmetro do átrio esquerdo quando comparado com os pacientes do grupo II (47,7±4,7mm vs 43.1±5,4 mm, p = 0,002 e 47,8±8mm vs 41,5±7,1mm, p = 0,003, respectivamente). Conclusões: 1. A presença de fibrose detectada pela tomografia computadorizada apresenta razoável sensibilidade para identificação de pacientes com risco para taquicardia ventricular; 2. A densidade de fibrose foi similar nos pacientes dos grupos I e II; 3. Pacientes com fibrilação atrial apresentaram maior densidade de fibrose ventricular detectada pela tomografia computadorizada em comparação aos pacientes sem fibrilação atrial; 4. O diâmetro diastólico final de ventrículo esquerdo e o diâmetro atrial esquerdo associaram-se à maior risco de taquicardia ventricular; 5. Os fatores de risco convencionais, associados ou não à fibrose, não se correlacionaram com maior probabilidade de ocorrência de eventos arrítmicos ventriculares. / Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy patients is still challenging. Primary prevention of sudden death with implantable cardioverter-defibrillator is an effective, however, costly and not risk-free method. Patients with implantable cardioverter-defibrillator indicated for primary prevention based on clinical risk factors display low rates of appropriate therapies. Studies evaluating new risk factors are needed seeking to identify who would be mostly at risk of sudden cardiac death, and therefore benefit from cardioverter-defibrillator. Studies have been conducted to establish a correlation between late enhancement and ventricular arrhythmias and sudden cardiac death; however, its clinical applicability is still controversial. Objective: To evaluate if the presence and extension of late enhancement, identified by computed tomography, correlates with the occurrence of ventricular arrhythmias in hypertrophic cardiomyopathy patients. Methods: Patients with hypertrophic cardiomyopathy followed in Electrophysiology and Cardiomyopathies divisions at Dante Pazzanese Institute of Cardiology were included in the study. Patients were divided into two groups: group I composed by those with appropriate therapies (shock or overdrive) or non-sustained ventricular tachycardia; and group II, composed by patients without documented ventricular arrhythmias. Continuous variables were compared using paired t-student test or Wilcoxon test. Categorical variables were analyzed using chi-square test. For data analysis, the SPSS program was used. P values < 0.05 were considered statistically significant. Results: Sixty one patients (mean age 39 ± 15 years, 51% female, average follow up 5.13 ± 3 years) were evaluated. In 91.8%, cardioveter-defibrillator was indicated by primary prevention. During the follow up, five patients (8.2%) had appropriate therapies and 15 (24.6%) presented non-sustained ventricular tachycardia without therapies. Fibrosis density, (including left ventricular mass compromise and percentage) was not statistically different between the groups (4.3±4.8% for group I vs. 7.0±7.7% for group II, p =0.13). However, 85% of patients with ventricular tachycardia had fibrosis on cardiac computed tomography. Larger fibrosis density correlated with younger age, reduced ejection fraction and male gender. Septum >30 mm correlated with fibrosis mass. There was a correlation between atrial fibrillation and higher left ventricular fibrosis percentage. Among the factors that correlated with higher fibrosis density, none of them had correlation with ventricular arrhythmic events. The combination of clinical factors that motivated the implantation of cardioverter-defibrillator did not correlate with arrhythmic events. Patients at group I had larger left ventricular diastolic diameter (47.7±4.7 vs. 43.1±5.4mm, respectively, p= 0.002) and left atrium diameter (47.8±8.2 vs. 41.5±7.1 mm, respectively, p=0.003). Conclusions: 1. The presence of fibrosis detected by cardiac tomography had reasonable sensitivity to identify patients at risk of ventricular tachycardia; 2. Fibrosis density was similar between groups I and II; 3. Patients with atrial fibrillation had more fibrosis density detected by cardiac tomography compared to patients without atrial fibrillation; 4. Left ventricular end diastolic diameter and left atrial diameter correlated with increased risk of ventricular tachycardia; 5. Classical risk factors, associated or not with fibrosis, did not correlate with increased probability of ventricular arrhythmic events.

Introdução: as sequelas de queimaduras na morfologia, mobilidade das estruturas motoras orais e nas funções orofaciais, como mastigação, deglutição e fala, são frequentes em pacientes com queimaduras graves na região de cabeça e pescoço. Objetivo: verificar a efetividade de um programa de reabilitação fonoaudiológica da motricidade orofacial em pacientes com queimaduras em cabeça e pescoço. Método: participaram da pesquisa 29 indivíduos encaminhados para avaliação e reabilitação ao Ambulatório de Funções da Face da Divisão de Fonoaudiologia do Instituto Central do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, no período de abril de 2016 a abril de 2018. Os critérios inclusão adotados na pesquisa foram: idade > = 6 anos; queimadura de terceiro grau caracterizada por perda epidérmica e dérmica em áreas de cabeça e pescoço; realização de tratamento cirúrgico prévio da ferida; ausência de falhas dentárias; presença de queixas relacionadas às alterações motoras orais; quadro clínico estável (conforme registros em prontuários médicos); alimentação por via oral exclusiva. Os pacientes foram divididos em dois grupos considerando o tempo da queimadura: Grupo 1 (G1) - pacientes com até um ano após a queimadura; Grupo 2 (G2) - pacientes com mais de um ano após a queimadura. A gravidade da queimadura foi determinada pela escala ABSI (The Abbreviated Burn Severity Index), aplicada no primeiro atendimento hospitalar do paciente. Todos os participantes foram submetidos à avaliação fonoaudiológica em dois momentos distintos, pré e pós-programa terapêutico. A avaliação foi composta pelos seguintes protocolos clínicos: Avaliação Miofuncional Orofacial com Escores Expandido (AMIOFE-E), verificação da amplitude mandibular (abertura oral máxima, lateralização para a direita e esquerda e protrusão mandibular) e medida antropométrica do canto de olho à comissura labial. O programa terapêutico adotado foi composto por 8 sessões semanais individuais, com duração de trinta minutos cada. O programa terapêutico foi composto por: manobras de compressão e alongamento em tecido cicatricial, manobras de alongamento intra e extra orais dos músculos da face, exercícios para mobilidade da musculatura da face e região cervical e exercícios para a adequação das funções de mastigação e deglutição. Resultados: a análise estatística evidenciou que o G2 apresentou idade significativamente maior que o G1. Nas análises intragrupos, tanto G1 quanto G2 apresentaram diferenças estatísticas para todos os itens do AMIOFE-E: aparência e condição postural; mobilidade e funções orofaciais (mastigação e deglutição). Quanto às medidas de amplitude mandibular, ambos os grupos apresentaram aumento significativo da medida de abertura oral máxima. Nas análises intergrupos, não foram observadas diferenças significativas entre G1 e G2, indicando que a melhora foi semelhante para ambos os grupos. Conclusão: a pesquisa comprova a eficácia do programa fonoaudiológico, baseado em evidências e com controle de resultados, em pacientes com queimaduras de terceiro grau em cabeça e pescoço. Os resultados demonstraram que ambos os grupos apresentaram melhora significativa na atividade miofuncional oral e na amplitude mandibular. Quando comparados os resultados obtidos entre G1 e G2, não foi observada diferença relevante, indicando que o tratamento proposto foi eficiente, independentemente do tempo entre a queimadura e o início do tratamento / Introduction: alterations in the morphology and mobility of the oral motor structures, and orofacial functions (i.e. mastication, swallowing and speech) are often observed in patients who suffered severe head and neck burns. Purpose: the purpose of the present study was to verify the effectiveness of a myofunctional orofacial rehabilitation program for patients with head and neck burns. Method: participants of this study were 29 individuals referred to the Division of Orofacial Myology of Instituto Central do Hospital das Clínicas of the School of Medicine, University of São Paulo, between April 2016 and April 2018, for oral motor assessment and rehabilitation. Inclusion criteria were as follows: age >= 6 years; third degree burns to the head and neck (i.e. epidermal and dermal loss); previous surgical treatment to the wound; complete dentition; oral motor alterations deficits; medical stability (according to medical records); receiving all nutrition by mouth. Patients were divided in two groups according to the onset of the injury: Group 1 (G1) - patients with injuries less than a year old; Group 2 (G2) - patients with injuries more than a year old. Burn severity was determined by the ABSI (The Abbreviated Burn Severity Index) according to the patient\'s first hospital record. All participants underwent clinical assessment that involved an oral motor evaluation (Expanded Protocol of Orofacial Myofunctional Evaluation with Scores - OMES-E), the assessment of the mandibular range of movements (maximal incisor distance, right and left lateral excursions and protrusion) and an anthropometric assessment (measurement of the distance between the commissures of mouth and the corners of the eyes). For comparison purposes, assessments were performed pre and post-treatment. The rehabilitation program involved 8 individual 30 minute weekly sessions. The rehabilitation program involved: compression and stretching maneuvers on the scar tissue; intra and extra oral stretching maneuvers of the facial muscles; facial and cervical muscles mobility exercises; mastication and swallowing exercises. Results: the statistical analysis indicated that G2 was significantly older than G1. When comparing pre and post-treatment results, both group of patients presented significant differences considering the items on the OMES-E (i.e. appearance and posture, mobility and orofacial functions), and the maximal incisor opening. The analysis comparing the performance of G1 and G2 did not indicate differences between the groups. Conclusion: The results of the study indicated that the rehabilitation program was effective for third degree burns on the head and neck, demonstrating significant improvement of the oral myofunctional parameters and of the maximal incisor opening. The results also suggest that the maturation of the scar tissue did not have an influence on the results of the treatment program

FUNDAMENTOS: Na cardiomiopatia hipertrófica (CMH) a disfunção diastólica do ventrículo esquerdo (VE) é causada por hipertrofia dos miócitos e fibrose intersticial. A Angiotensina II (Ang II) pode promover hipertrofia, fibrose e alteração de relaxamento miocárdico. Na hipertrofia secundária a hipertensão o bloqueio dos receptores tipo 1 (AT1) da Ang II diminui a hipertrofia e a fibrose e, em animais com CMH losartan causou reversão da fibrose miocárdica. Os efeitos do antagonismo da Ang II na CMH humana não são conhecidos. OBJETIVOS: Avaliar os efeitos do losartan, um bloqueador dos receptores AT1 da Ang II, sobre a hipertrofia e a função diastólica do VE em pacientes com CMH não obstrutiva. CASUÍSTICA E MÉTODO: Foram estudados 27 pacientes consecutivos portadores de CMH na forma não obstrutiva, com média de idade de 34,4 anos, sendo 14 homens, que receberam losartan 100 mg/dia durante 6 meses. Antes do tratamento e ao final do mesmo foram avaliadas: a classe funcional (CF), a hipertrofia e a função diastólica do VE esquerdo pela ecocardiografia (modo-M, Doppler mitral, venoso pulmonar e Doppler tecidual do anel mitral) e a concentração plasmática do fragmento amino-terminal do pro-peptídeo natriurético tipo B (NT-proBNP). Valores bi-caudais de p<0,05 em testes pareados foram considerados estatisticamente significantes. v RESULTADOS: CF - dos 19 pacientes sintomáticos antes do tratamento, 8 (42%) tornaram-se assintomáticos (p=0,008). A CF média passou de 2,04±0,81 para 1,48±0,64 (p=0,0001). Doppler ecocardiografia - redução do diâmetro atrial esquerdo de 43,3±6,2 mm para 40,5±6,1 mm (p<0,0001), diminuição da velocidade da onda atrial reversa do fluxo venoso pulmonar de 36,4±9,7 cm/s para 32,2±6,2 cm/s (p=0,008), aumento da velocidade diastólica inicial (Ea) do anel mitral de 10,7±3,2 cm/s para 11,95±3,01 cm/s (p=0,004), aumento da razão Ea/Aa de 1,11±0,36 para 1,33±0,48 (p=0,009), e diminuição da razão E/Ea de 8,37±5,4 para 6,46±3,2 (p=0,004). Não ocorreram modificações nas espessuras parietais nem nos diâmetros do VE. NT-proBNP - diminuição do valor mediano de 652 pg/ml para 349 pg/ml, assim como dos quartis e dos valores máximo e mínimo (p=0,003). CONCLUSÃO: Em pacientes com CMH não obstrutiva o antagonismo da angiotensina II com losartan 100 mg/dia durante 6 meses resultou em melhora bioquímica e da função diastólica do VE, sem evidente regressão de hipertrofia ao ecocardiograma. Esses resultados são promissores e indicam possíveis benefícios que podem ser obtidos com medicamentos que atuam inibindo o sistema renina-angiotensina em pacientes com CMH. / BACKGROUND: In hypertrophic cardiomyopathy (HCM) diastolic dysfunction of the left ventricle (LV) is caused by myocite hypertrophy and interstitial fibrosis. Angiotensin II (Ang II) has trophic and profibrotic effects on the heart, and may impair myocardial relaxation. In hypertensive LV hypertrophy Ang II type 1 (AT1) receptors blockade can reverse hypertrophy and fibrosis, and in animals with HCM, losartan reversed myocardial fibrosis. The effects of Ang II antagonism in humans with HCM are unknown. OBJECTIVES: To evaluate the effects of losartan, an AT1 blocker, in patients with non-obstructive HCM, with emphasis on LV diastolic function. PATIENTS AND METHODS: 27 consecutive patients, mean age 34.4 years, 14 males, were treated with losartan 100 mg/day during 6 months. Evaluations were performed at baseline and at 6 months, as follows: functional class (FC), left atrium diameter (LAD), LV hypertrophy and LV diastolic function (M-mode echocardiography, mitral flow and pulmonary venous flow Doppler, mitral annulus tissue Doppler), and plasma concentrations of the amino-terminal fragment of proBNP (NT-proBNP). RESULTADOS: FC - of the 19 symptomatic patients before the treatment, 8 (42%) were free of symptoms at 6 months (p=0.008). There were no changes in LV wall and cavity measures. LAD decreased from 43.3±6.2 mm to 40.5±6.1 mm (p<0.0001), and pulmonary venous atrial reverse velocity decreased from 36.4±9.7 cm/s to 32.2±6.2 cm/s (p=0.008). Tissue Doppler: mitral annulus early diastolic velocity (Ea) increased from 10.7±3.2 cm/s to 11.95±3.01 cm/s (p=0.004), Ea/Aa ratio increased from 1.11±0.36 to 1.33±0.48 (p=0.009), and E/Ea ratio decreased from 8.37±5.4 to 6.46±3.2 (p=0.004). NT-proBNP - there was a decrease in the median value from 652 pg/ml to 349 pg/ml, as well as a decrease in quartiles, maximum and minimum values (p=0.003). CONCLUSION: In patients with non-obstructive HCM, treatment with losartan 100 mg/day during 6 months resulted in Doppler echocardiographic and biochemical changes indicative of LV diastolic function amelioration, in the absence of evident LV hypertrophy regression. These preliminary results are promising and suggest that inhibition of the renin-angiotensin system may be benefic in human HCM

Les fibroses anormales sont responsables de plus de 40% des décès pour raison médicale ; elles se développent suite à une inflammation chronique. Les fibroses hépatiques causées par les schistosomes et par le virus HCV sont en grande partie déterminées par la génétique du malade. Notre thèse a consisté à poursuivre le travail de caractérisation du déterminisme génétique des fibroses hépatiques et cutanées.La première partie de notre thèse, est l’étude informatique et statistique des données de génotypage GWAS de Brésiliens qui présentent une fibrose hépatique bilharzienne grave sur plus de 2,5 millions de SNPs. 180 SNPs qui montraient une association suggestive avec les fibroses graves ont été sélectionnés, dont certains affectent les gènes des voies Wnt. Ces SNPs ont été testés sur une cohorte de 460 pêcheurs ougandais exposés à S.mansoni et nous avons confirmé l’association avec la fibrose de 4 SNPs.La deuxième partie de notre thèse est l’analyse transcriptômique (RNA-Seq) des mécanismes responsables des fibroses anormales de la peau de sujets affectés par des fibroses chéloïdes de 20 tissus chéloïdes, 7 tissus sains et 7 tissus affectés par des cicatrices hypertrophiques. Cette analyse montre que le développement des chéloïdes est la conséquence d’une stimulation anormale des voies de la cicatrisation en partie due à l’activation de la voie Wnt βcatenin et Wnt PCP. Pour conforter cette proposition, nous avons effectué une analyse génétique de la voie Wnt dans deux cohortes indépendantes. L’analyse statistique montre que des SNPs dans 6 gènes de la voie Wnt βcatenin contribuent au développement des fibroses chéloïdes. / Abnormal fibrosis is responsible for more than 40% of medical deaths. They develop as a result of chronicinflammation. Hepatic fibroses caused by schistosomes andHCV virus are largely determined by the genetic background of the patient. Our thesis consisted of continuing thework of characterizing the genetic determinism of liver and skin fibrosis.The first part of our thesis is the computer and statistical study of GWAS genotyping data of Brazilians whohave severe bilharzeal liver fibrosis on more than 2.5 million SNPs. 180 SNPs that showed suggestive associationwith severe fibrosis were selected, some of which affect the Wnt pathway. These SNPs were then tested on a cohortof 460 Ugandan fishers exposed to S.mansoni and the results confirmed the association of 4 SNPs with fibrosis.The second part of our thesis is the genomic analysis (transcriptome and genetics) of the mechanismsresponsible for the abnormal skin fibrosis with subjects affected by keloid scars. We performed an analysis of genes(RNASeq) expressed differently between 20 keloids, 7 healthy tissues and 7 tissues affected by hypertrophic scars.This analysis shows that the development of keloids is the consequence of an abnormal stimulation of cicatrizationpathways with strong activation of the Wnt βcatenin and Wnt PCP pathway. To support this proposal, we performeda genetic analysis of the Wnt pathway in two independant cohorts.The statistical analysis of the results shows that polymorphisms in 6 genes of the Wnt βcatenin pathway contributeto the development of keloid fibrosis.

Background - Regular exercise reduces the risk of cardiovascular disease and subsequent sudden cardiac death (SCD). However, a small, but notable proportion of athletes die suddenly due to inherited or congenital disorders of the heart that predispose to malignant ventricular arrhythmias. Such tragedies are highly publicised, particularly when high-profile athletes are involved. To date, limited evidence for the efficacy of cardiovascular pre-participation screening exists outside of the Italian experience. Furthermore, limited data exists examining the impact of ethnicity on cardiac adaptations to physical training. Whilst the cardiovascular benefits of exercise are well known, the impact of life-long endurance exercise is less well understood. Long term high-intensity endurance exercise is associated with changes in cardiac morphology together with electrocardiographic alterations that are believed to be physiologic in nature. Recent data however, has suggested a number of deleterious adaptive changes in cardiac structure, function and electrical activity in response to life-long endurance activity. Aims and Objectives - The aims of this PhD were; 1) To find an effective preparticipation screening method that would successfully identify pre-existing cardiovascular abnormalities, 2) To identify the prevalence of hypertrophic cardiomyopathy and Long QT syndrome in elite UK athletes; 3) To examine the impact and significance of ethnicity upon left ventricular remodelling in elite athletes, and 4) To examine the acute and chronic impact of ultra-endurance exercise across the life-span in male endurance athletes. Major Results and Conclusions – 1) Study 2 sought to confirm the efficacy of resting 12-Lead ECG ‘alongside’ personal/family history questionnaires and physical examinations as collective tools to identify diseases that have the potential of causing sudden death within a cohort of elite junior athletes (n=1074) and physically active school children (n=1646). Nine participants were identified with a positive diagnosis of a disease associated with SCD. None of those diagnosed with a disease associated with SCD were symptomatic or had a family history of note. Thus, personal symptoms and family history questionnaires alone are inadequate in the identification of individuals with diseases associated with SCD. In conclusion, resting 12-Lead ECG is paramount when screening for diseases that have the potential of causing sudden death in the young. 2) Study 3 examined 3,500 asymptomatic elite athletes (75% male) with a mean age of 20.5 ± 5.8 years with 12-lead ECG and 2-dimensional echocardiography. None had a known family history of HCM. Of the 3,500 athletes, 53 (1.5%) had LVH (mean 13.6 ± 0.9mm, range 13 to 16mm), and of these 50 had a dilated LV cavity with normal diastolic function to indicate physiological left ventricular hypertrophy. Three (0.08%) athletes with LVH had a non-dilated LV cavity and associated deep T-wave inversion that could have been consistent with HCM. However, none of the 3 athletes had any other phenotypic features of HCM on further non-invasive testing and none had first-degree relatives with features of HCM. In conclusion, the prevalence of HCM in elite athletes is significantly less than in the general population; with the demands of strenuous exercise on the cardiovascular system selecting out most individuals with HCM. Study 4 examined 2000 elite athletes in order to identify the prevalence of Long QT syndrome. Three athletes had a QTc value of >500 ms and all exhibited one of: paradoxical prolongation of QTc during exercise, a confirmatory genetic mutation, or prolonged QTc in a first-degree relative. In contrast, none of the athletes with a QTc value of <500 ms had any other features to indicate LQTS. Accordingly, the prevalence of a prolonged QTc interval in elite British athletes is 0.4%. 3) Study 6 examined 300 nationally ranked UK black male athletes (mean age 20.5 years) in comparison to 150 black and white sedentary individuals and 300 highly-trained white male athletes. Black athletes exhibited greater LV wall thickness and cavity size compared with sedentary black and white individuals. Black athletes had greater LV wall thickness compared with white athletes. A minority of black athlete’s exhibit LVH ≥15 mm; proposing that in the absence of cardiac symptoms or a family history of HCM, an LV wall thickness ≥15 mm in black athletes may represent physiologic LVH when the LV cavity is enlarged and diastolic indexes are normal. 7 black athletes (12%) with LVH displaying deep T-wave inversions in leads V1 to V4. In conclusion, in the absence of obvious pathology, these electrical anomalies in black athletes likely represent a normal spectrum of ECG changes in response to physical training. 4) Study 8 examined 17 male participants (age 33.5 ± 6.5 years, 26–40 years) using cardiac magnetic resonance (CMR) and echocardiography before and after a marathon to investigate the relationship between systolic function and diastolic function against biomarkers of cardiac damage. Results demonstrates biomarkers of myocardial cell damage following an acute bout of prolonged exercise are not associated with either systolic or diastolic functional measures, and do not seem to be associated with any detectable myocardial inflammation, oedema, or scarring using either gold standard techniques of gadolinium enhanced CMR or echocardiography respectively. The impact of multiple episodes of prolonged exercise, as experienced by highly trained veteran endurance athlete is not fully understood. 5) Study 10 examined the cardiac structure and function of 12 life-long, competitive endurance veteran athletes (> 50 yrs, mean ± SD marathons 178 ± 209 (range 20 – 650)) against 17 young male endurance athletes (<40 yrs) using echocardiography and CMR with late gadolinium enhancement (LGE) to assess myocardial fibrosis. Lifelong veteran athletes had smaller LV and RV end-diastolic and end-systolic volumes (p<0.05) but maintained LV and RV systolic function compared with young athletes. In 6 (50%) of the veteran athletes LGE of CMR indicated the presence of myocardial fibrosis; no LGE in the young athletes. The prevalence of LGE in veteran athletes was not associated with the number of competitive marathons or ultra-endurance marathons (>50 miles) completed, age, LV and RV end-diastolic volumes or LV mass (p>0.05). In conclusion, there is limited evidence at present demonstrating that cardiovascular re-modelling following lifelong endurance exercise leads to long-term disease progression, cardiovascular disability or SCD.

La grossesse induit de profonds changements hémodynamiques et métaboliques de l’organisme maternel qui ont des conséquences sur le cœur. L’adaptation du cœur à cette condition physiologique nécessite un remodelage de sa structure et par conséquent des ajustements de sa fonction. Les mécanismes responsables de ces adaptations sont en grande partie inconnus. Cependant, ces connaissances sont essentielles pour la compréhension des complications cardiovasculaires, telle que l’hypertension gestationnelle (HG), qui constituent un risque pour la santé de la mère et du fœtus. Afin de caractériser les adaptations du cœur lors de la grossesse, l’originalité de notre approche expérimentale consistait à étudier le remodelage à l’échelle des cardiomyocytes du ventricule gauche. Ainsi, notre premier objectif était de déterminer les modifications structurales et fonctionnelles des cardiomyocytes chez la rate en vue d’identifier les altérations lors de l’HG. Chez les rates gestantes, le remodelage structural des cardiomyocytes se caractérise par une hypertrophie cellulaire avec une augmentation proportionnelle des dimensions. L’HG a été induite par un supplément sodique (0.9% NaCl) dans la diète. L’inadaptation structurale lors de l’HG se traduit par une diminution du volume cellulaire. L’étude des modifications fonctionnelles a révélé que lors de la gestation le fonctionnement contractile des cellules est dépendant de l’adaptation du métabolisme maternel. En effet, les substrats énergétiques, lactate et pyruvate, induisent une augmentation de la contractilité des cardiomyocytes. Cet effet est plus faible dans les cellules des rates hypertendues, ce qui suggère des anomalies du couplage excitation-contraction, dans lequel les courants calciques de type L (ICa-L) jouent un rôle important. Paradoxalement, le lactate et le pyruvate ont induit une augmentation de la densité des courants ICa-L seulement chez les rates hypertendues. Le récepteur aux minéralocorticoïdes (RM) est connu pour son implication dans le remodelage structuro-fonctionnel du cœur dans les conditions pathologiques mais pas dans celui induit par la grossesse. Notre deuxième objectif était donc de déterminer le rôle du RM dans l’adaptation de la morphologie et de la contractilité des cardiomyocytes. Des rates gestantes ont été traitées avec le canrénoate de potassium (20 mg/kg/jr), un antagoniste des RM. L’inhibition des RM pendant la gestation empêche l’hypertrophie cellulaire. De plus, l’inhibition des RM bloque l’effet du lactate et du pyruvate sur la contractilité. Chez la femme, la grossesse est associée à des changements des propriétés électriques du cœur. Sur l’électrocardiogramme, l’intervalle QTc est plus long, témoignant de la prolongation de la repolarisation. Les mécanismes régulant cette adaptation restent encore inconnus. Ainsi, notre troisième objectif était de déterminer le rôle du RM dans l’adaptation de la repolarisation. Chez la rate gestante, l’intervalle QTc est prolongé ce qui est corroboré par la diminution des courants potassiques Ito et IK1. L’inhibition des RM pendant la gestation empêche la prolongation de l’intervalle QTc et la diminution des courants Ito. Les travaux exposés dans cette thèse apportent une vision plus précise du remodelage cardiaque induit par la grossesse, qui est permise par l’étude à l’échelle cellulaire. Nos résultats montrent que lors de la gestation et de l’HG les cardiomyocytes subissent des remodelages morphologiques contrastés. Notre étude a aussi révélé que lors de la gestation, la fonction contractile est tributaire des adaptations métaboliques et que cette relation est altérée lors de l’HG. Nos travaux montrent que la régulation de ces adaptations gestationnelles fait intervenir le RM au niveau de la morphologie, de la relation métabolisme/fonctionnement contractile et de la repolarisation. En faisant avancer les connaissances sur l’hypertrophie de la grossesse, ces travaux vont permettre d’améliorer la compréhension des complications cardiovasculaires gestationnelles. / Pregnancy is characterized by marked hemodynamic and metabolic changes, which have consequences on the heart. The adaptation of the heart to this physiological situation requires a remodeling of its structure, and consequently functioning adjustments. Mechanisms responsible for these adaptations are largely unknown. However, this knowledge is essential for the understanding of cardiovascular complications, such as gestational hypertension (GH), which represents a risk for the mother and the fœtus. To characterize cardiac adaptations to pregnancy, our experimental approach consisted in studying this remodelling at the level of left ventricle cardiomyocytes. Therefore, our first objective was to determine structural and functional modifications of cardiomyocytes in pregnant rats to be able to identify their variations in GH. In pregnant rats, structural remodelling of cardiomyocytes was characterized by a proportional volume expansion. GH was induced by a high sodium supplement (0.9% NaCl). In hypertensive rats, we observe significant cell volume shrinkage. The study of functional modifications elicited a strong relationship between metabolic adaptations and cell contractility. According to our results, in pregnant rats cardiomyocyte contractility was increased in presence of energy substrates lactate and pyruvate. This effect was weaker in the cells from hypertensive rats. This suggested modifications of the excitation-contraction coupling, in which L-type calcium currents (ICa-L) play an important role. Unexpectedly, lactate and pyruvate induced a significant increase in ICa-L only in hypertensive rats. In pathological conditions, mineralocorticoid receptors (MR) have been shown to mediate structural as well as functional remodelling of the heart. Our study is the first to investigate MR involvement in cardiac remodelling during pregnancy. Thus, our second objective was to determine MR involvement in cardiomyocyte remodelling. For this study, pregnant rats were treated with potassium canrenoate of (20 mg / kg / day), a MR antagonist. Our results revealed that MR inhibition during the pregnancy elicited a significant decrease of cell volume. MR inhibition has also affected metabolism and cellular functioning relationship. Indeed, plasma concentration of lactate was lower, which was in correlation with its blunted effect on cell contractility. In women, pregnancy-induced hypertrophy is associated with changes in electrical properties of the heart. Indeed, repolarisation is prolonged, which is characterised by a longer duration of QTc interval on the electrocardiogram. Regulation mechanisms involved in this adaptation are still largely unknown. Our third objective was therefore to determine the role of MR in the adaptation of repolarisation to pregnancy. Pregnancy induced a prolongation in QTc interval, which correlates with a decrease in potassium currents Ito and IK1. MR inhibition prevented QTc interval prolongation and the lowering of Ito. Our study gives a new insight of pregnancy-induced cardiac hypertrophy, which is provided by investigations at the cellular level. Our results demonstrate that pregnancy and GH are characterised by opposite remodellings. Moreover, in pregnancy the contractile function is dependent on metabolic adaptations. This is all the more glaring in GH as metabolic alterations induced modifications of electric properties to maintain contractile functioning. Furthermore, our work reveals MR involvement in the regulation of morphology, metabolism/contractility relationship, and repolarisation. By improving the knowledge of hypertrophy during pregnancy, this work contributes to improve the understanding of pregnancy-induced cardiac complications.

Hypertrophic scarring is a common occurrence for severe burn victims leading to major functional, physiological, and aesthetic effects to the patients. Limiting the hypertrophic scarring of the patients alleviates the functional, physiological, and aesthetic effects. Silicone gels, over the past decade, have been widely used to remediate and limit hypertrophic scarring but the mechanism of action is yet to be determined. One explanation has been that hydration of the outermost area of the burn is induced by the silicone gel . However, non-silicone polymers which increase hydration could not mimic the effect. An alternative interpretation is that there may be silicone species that migrate from the silicone gel into the viable tissue to mediate reactions in the extra-cellular matrix that result in a decreased deposition of excessive amounts of collagen - a central feature of the hypertrophic scar. A novel and informative technique to study these species is MALDI-TOF/MS (Matrix Assisted Laser Desorption Ionisation-Time of Flight Mass Spectrometry) in conjunction with gel permeation chromatography. MALDI-TOF/MS, which has allowed the detection of intact molecular species that were not possible with more established mass spectrometric techniques. The mobile species that may migrate from polydimethylsiloxane medical gel sheeting into skin have been identified by MALDI-MS. The bulk gel contains predominantly cyclic oligomers with a mass distribution peaking at n = 19 (number of repeating siloxane units), but in an aqueous environment the species at the surface of the silicone medical gel are predominantly methyl/methylol-terminated linear siloxanes. By using a gelatine matrix as a model substrate, the distribution of silicon after application of the silicone gel for 16 weeks was determined by Energy-dispersive X-Ray mapping of the sectioned gelatine. The association of the linear and cyclic oligomers with proteins relevant in hypertrophic scarring are considered. The mobility of silicone species across stratum corneum was confirmed by Attenuated Total Reflectance Fourier Transform Infrared spectroscopy (ATR-FT/IR). This method confirms our hypothesis that not only are the low molecular weight silicone species mobile, but also that they do traverse the natural barrier, the stratum corneum, to levels that are detectable by ATR after a continuous application over approximately 11 days. Invitro studies of the effects of LMWS on primary line fibroblast cells indicate a response that down regulates the proliferation of fibroblast cells and protein production. Preliminary results indicate that a family of pendant functional LMWS are effective in down regulating hypertrophic-derived fibroblast primary cells. Studies on hypertrophic scar tissue treated with silicone medical gel indicate that LMWS permeate across the stratum corneum into viable scar tissue. In some areas, the LMWS tend to pool as detected by SEM/EDX elemental silicon analysis. These areas of LMWS pooling tend to be composed of highly disorganised collagen nodules.

Made available in DSpace on 2016-06-02T19:22:58Z (GMT). No. of bitstreams: 1 5212.pdf: 1422285 bytes, checksum: 87b49935d019c76fe85fe17404e72415 (MD5) Previous issue date: 2013-03-25 / Universidade Federal de Sao Carlos / Dexamethasone (Dexa) has been widely used as anti-inflammatory and anti-allergic treatment, however, its chronic use provokes peripheral insulin resistance, hypertension, weight loss and muscle atrophy. Low intensity aerobic training has been indicated for prevention and treatment of diabetes, hypertension and metabolic syndrome, however, its effects on muscle atrophy are still uncertain. Muscle atrophy may be determined by an imbalance between atrophic (FOXO3a, atrogin-1, Murf-1) and hypertrophic (AKT, mTOR) proteins, but almost nothing is known about the effects of Dexa on these proteins. Resistance training (RT) has been recommended for treatment of pathologies which involves muscle atrophy, however little is known about the effects of low intensity RT on the muscle atrophy induced by Dexa. This study investigated whether low intensity RT, performed before and concomitant with Dexa treatment could prevent and / or attenuate muscle atrophy induced by Dexa. Also, it examined the role of proteins that control muscle homeostasis in this response. Forty-eight rats were allocated into 4 groups: sedentary control (SC), sedentary and treated with Dexa (SD), trained control (TC) and trained and treated with Dexa (TD). After an adaptation period, the rats underwent to an resistance exercise protocol (ladder,60% maximal loading, 5 days / week, 70 days) or kept sedentary. During the last 10 days, the rats were treated with Dexa (0.5 mg / kg of bodyweight per day, i.p.). Fasting glycemia was measured before and after exercise training and treatment periods. Bodyweight (BW) was measured weekly before treatment and daily during drug treatment. The tibialis anterior (TA), flexor hallucis longus (FHL) and soleus muscles were removed and homogenized. Protein production of AKT, mTOR, FOXO3a, atrogin-1 and Murf-1 was analyzed in the muscles. Two-way ANOVA with Tukey post-hoc were used (p<0.05). Dexa treatment increased glycemia by 46%, reduced BW by 19% and food intake by 45% in sedentary animals. The RT, that was effective to increase physical capacity of the rats (+118%) prevented the increase in glycemia, but did not avoid the BW reduction. Dexa provoked TA muscle atrophy (-21%), which was determined by reduction of AKT (-29%) and increase of Murf-1 (+25%). RT attenuated the increased the Murf-1 protein production (-37%), however it did not avoid TA muscle atrophy. In the FHL, it was observed muscle atrophy (-28%) determined by reduction of AKT (-27%) and increase of Murf-1 (+55%). RT increased mTOR in TC (+36%) and TD (+72%) groups and also reduced atrogin-1 protein production in TD, which contributed to attenuate FHL muscle atrophy. Soleus muscle was not altered neither by training nor treatment. These data together suggest that low intensity RT was effective in attenuating FHL muscle atrophy due to a combination of increase in hypertrophic and decrease in atrophic protein production. / A Dexametasona (Dexa) vem sendo amplamente usada no tratamento de inflamações e alergias, porém seu uso crônico provoca resistência periférica à insulina, hipertensão arterial, perda de peso corporal e atrofia muscular. O exercício físico aeróbio contínuo, de baixa intensidade, tem sido empregado na prevenção e tratamento de diabetes, hipertensão arterial e síndrome metabólica, no entanto, seus efeitos sobre a atrofia muscular ainda são incertos. Atrofia muscular pode ser determinada por um desequilíbrio entre proteínas atróficas (FOXO3a, atrogina-1 Murf-1) e hipertróficas (AKT, mTOR), mas quase nada se sabe sobre os efeitos da Dexa sobre estas proteínas. O exercício resistido (TR) tem sido recomendado como tratamento de patologias que envolvem atrofia muscular, no entanto pouco se sabe sobre os efeitos do TR de baixa intensidade sobre a atrofia muscular induzida pela Dexa. Este estudo investigou se o TR de baixa intensidade, realizado antes e concomitante ao tratamento com Dexa, poderia prevenir e/ou atenuar a atrofia muscular. Além disso, verificou o papel das proteínas que controlam a homeostase muscular nesta resposta. Quarenta e oito ratos foram alocados em 4 grupos: sedentário controle (SC), sedentário e tratado com Dexa (SD), treinado controle (TC) e treinado e tratado com Dexa (TD). Após um período de adaptação, este ratos foram submetidos ao protocolo de treinamento resistido (escalada, 60% do carregamento máximo, 5 dias / semana, 70 dias) ou mantidos sedentários. Durante os últimos 10 dias, os animais foram tratados com Dexa (0,5 mg/kg de peso corporal por dia, i.p.). A glicemia de jejum foi medida antes e após os períodos de treinamento físico e tratamento com a Dexa. O peso corporal (PC) foi mensurado semanalmente antes do tratamento e diariamente durante o tratamento. Os músculos tibial anterior (TA), flexor longo do Halux (FHL) e sóleo foram retirados e homogeneizados. Verificou-se a produção das proteínas AKT, mTOR, FOXO3a, Atrogina-1 e Murf-1 nos músculos. Anova de 2 caminhos, com post-hoc de Tukey, foram utilizados (p<0,05). O tratamento com Dexa determinou aumento da glicemia de jejum em 46%, redução de 19% do PC e de 45% na ingestão alimentar nos sedentários. O TR, que foi efetivo em aumentar a capacidade física dos animais (+118%) preveniu o aumento da glicemia, mas não atenuou a redução de PC. A Dexa promoveu atrofia muscular no TA (-21%), que foi causada por redução da produção proteica de AKT (-29%) e aumento da Murf-1 (+25%). O TR atenuou o aumento da Murf-1 (- 37%), no entanto, não foi efetivo em atenuar a atrofia no TA. No FHL, ocorreu atrofia (-28%) determinada pela redução da AKT (-27%) e aumento da Murf-1 (+55%). O TR promoveu aumento da mTOR no TC (+36%) e no TD (+72%) bem como reduziu a produção proteica de atrogina-1 no TD, o que contribuiu para atenuar a atrofia muscular no FHL. O sóleo não foi alterado nem pela Dexa nem pelo TR. Estes dados sugerem que o TR, de baixa intensidade, foi eficaz em atenuar a atrofia muscular no FHL por uma combinação entre redução de proteínas atróficas acompanhada de aumento de proteínas hipertróficas

Conselho Nacional de Desenvolvimento Científico e Tecnológico / This doctoral thesis involved the study of three groups of neoplasms that affect bones of dogs (primary bone neoplasms, bone metastases, and multicentric neoplasms with bone involvement) and a bone lesion, often paraneoplastic, known as hypertrophic osteopathy. The study of primary bone neoplasms covered important pathological and epidemiological aspects for the diagnosis of this group of tumors, with emphasis on osteosarcomas. It was retrospectively performed, covering a period of 22 years. Reports of biopsy and necropsy cases of dogs received at the Laboratório de Patologia Veterinária, Universidade Federal de Santa Maria (LPVUFSM) were analyzed. Out of the 90 primary bone neoplasms diagnosed in this period, 89 were malignant. Osteosarcoma was the most prevalent (86.7%) neoplasm. Regarding osteosarcomas, most cases occurred in large and giant breed dogs, between six and 10 years of age. The neoplasms predominantly involved the appendicular skeleton and were 3.5 times more prevalent in the forelimbs than in the hindlimbs. The predominant histologic subtype was the osteoblastic. For the study of neoplasms that comprise the second and third groups, i.e., neoplasms with bone metastases or with bone involvement by multicentric neoplasms, a prospective study was conducted over a period of three years. The skeleton of 110 dogs, with 118 malignant neoplasms of different origins received in the necropsy service of the LPV-UFSM were examined for bone lesions. Twenty-one cases of bone metastases or bone involvement by multicentric neoplasms (19.1%) were detected. In general, the bone lesions affected more female dogs. However, when mammary gland neoplasms were not considered, the distribution of cases according to the sex was very similar. The mean age was 9-years-old and dogs of different breeds were affected. The mammary gland was the primary site of most bone metastases, followed by neoplasms of the musculoskeletal and respiratory systems. Most metastases were observed grossly and occurred in multiple bones. However, in 23% of the cases metastases could only be observed microscopically. Vertebrae and humerus were the mosdt frequently affected bones. Simultaneously, seven cases of hypertrophic osteopathy, diagnosed in a period of 11 years at the LPV-UFSM, were retrospectively and prospectively studied. Affected dogs had clinical signs of bone involvement and lesions mainly in the long bones of the limbs. The lesions consisted of periosteal bone neoformation, detected on radiographs, bone inspection during necropsy, and with great level of detail, in macerated bone specimens. The bone proliferation was partially circumferential and occurred mainly in the diaphysis of long bones. It consisted of bone trabeculae of irregular size and thickness, which were arranged perpendicularly to the original cortical bone. In all cases, the lesions of hypertrophic osteopathy were associated with lung neoplasms (primary or metastatic). In two of the seven cases, the lung metastases were of primary bone sarcomas and, in one case, there was a primary lung osteosarcoma (extra-skeletic). / Esta tese envolveu o estudo de três grupos de neoplasmas que afetam os ossos de cães (neoplasmas ósseos primários, metástases ósseas e neoplasmas multicêntricos com envolvimento ósseo) e uma alteração óssea, muitas vezes paraneoplásica, conhecida como osteopatia hipertrófica. O estudo dos neoplasmas ósseos primários envolveu aspectos epidemiológicos e patológicos importantes para o diagnóstico deste grupo de tumores, com ênfase nos osteossarcomas. Foi realizado de forma retrospectiva, compreendo um período de 22 anos. Foram analisados laudos de casos de biópsias e necropsias de cães recebidos no Laboratório de Patologia Veterinária da Universidade Federal de Santa Maria (LPV-UFSM). Dos 90 neoplasmas ósseos primários diagnosticados neste período, 89 eram malignos, sendo os osteossarcomas os mais prevalentes (86,7%). Em relação aos osteossarcomas, a maioria dos casos ocorreu em cães de raças grandes e gigantes e entre seis e 10 anos de idade. Os neoplasmas envolvendo o esqueleto apendicular predominaram e foram 3,5 vezes mais prevalentes nos membros anteriores que nos posteriores. O subtipo histológico predominante foi o osteoblástico. Para o estudo dos neoplasmas que compreenderam o segundo e o terceiro grupos, ou seja, neoplasmas com metástases ósseas ou o envolvimento ósseo em neoplasmas multicêntricos, foi realizado um estudo prospectivo durante um período de três anos. Neste período, cães provenientes do serviço de necropsias do LPV-UFSM foram avaliados. O esqueleto de 110 cães portadores de 118 neoplasmas malignos de diferentes origens foi examinado em busca de lesões ósseas. Foram encontrados vinte e um casos de metástases ou neoplasmas multicêntricos com envolvimento ósseo (19,1%). Em geral, as lesões ósseas afetaram mais as fêmeas. No entanto, quando os neoplasmas originados na glândula mamária foram desconsiderados, a distribuição dos casos de acordo com o sexo foi muito semelhante. Foram afetados cães com idade média de 9 anos e de diferentes raças. A glândula mamária foi a origem da maioria dos tumores que metastatizaram para os ossos, seguida do sistema músculo-esquelético e respiratório. A maioria das metástases foi detectada macroscopicamente e ocorreu em múltiplos ossos. Entretanto, em 23% dos casos as metástases só puderam ser observadas microscopicamente. Dentre os ossos afetados, vértebras e úmero foram os mais frequentemente acometidos. Paralelamente foram estudados, de forma retrospectiva, sete casos de osteopatia hipertrófica diagnosticados em um período de 11 anos no LPV-UFSM. Os cães afetados apresentavam sinais clínicos indicativos de envolvimento ósseo e lesões macroscópicas principalmente nos ossos longos dos membros. As lesões consistiram de neo-formação óssea periosteal, detectada em exame radiográfico, na inspeção óssea durante a necropsia e, com grande nível de detalhamento, em espécimes ósseos macerados. A proliferação óssea observada era parcialmente circunferencial e ocorreu principalmente na diáfise dos ossos longos. Era constituída por trabéculas ósseas de tamanho e espessura irregulares que estavam dispostas de forma perpendicular ao córtex ósseo original. Em todos os casos, as lesões de osteopatia hipertrófica foram associadas a neoplasmas pulmonares (primários ou metastáticos). Em dois dos sete casos, as metástases pulmonares eram de sarcomas ósseos e, em um caso, havia um osteossarcoma primário pulmonar (extraesquelético).

O estudo de mutações genéticas como causa das cardiomiopatias teve início com a descoberta de mutações em proteínas sarcoméricas que levavam à Cardiomiopatia Hipertrófica, desde então, alterações em diversos genes, de proteínas contráteis ou não, foram descobertas e listadas como a responsável pelo desenvolvimento de diferentes cardiomiopatias. Estudar o efeito destas mutações nos cardiomiócitos destes pacientes permanecia um desafio devido ao difícil acesso às células cardíacas. Em 2007, a técnica de reprogramação de células somáticas em células-tronco pluripotentes foi descoberta. Pelo fato das células-tronco pluripotentes serem capazes de ser diferenciadas em cardiomiócitos, surgiu-se a possibilidade de se estudar essas células de indivíduos portadores das mutações genéticas. Esta tese teve como objetivo a criação de um modelo celular para estudar a Cardiomiopatia Hipertrófica causada por mutações genéticas. Inicialmente foi estabelecido um protocolo de reprogramação celular para se estabelecer linhagens celulares das células-tronco induzidas de um paciente com mutação no gene MYH7. Tendo as células caracterizadas, elas foram diferenciadas em cardiomiócitos através de um protocolo adaptado de protocolos de diferenciação direta em cardiomiócitos. Os cardiomiócitos gerados apresentaram características moleculares e funcionais semelhantes à cardiomiócitos primários humanos e foi visualizado, através de microscopia eletrônica de transmissão, que os cardiomiócitos do paciente com alteração genética possuíam grande proporção de sarcômeros desorganizados em comparação a cardiomiócitos de indivíduos saudáveis. Em conclusão, o modelo celular desenvolvido sugere ser possível o estudo do efeito de mutações genéticas em Cardiomiopatia Hipertrófica. / The study of genetic mutations as the cause of cardiomyopathies initiates with the discovery of mutations in sarcomeric proteins genes that lead to Hypertrophic Cardiomyopathy. Since then, mutations in several genes, coding to sarcomeric proteins or not, were discovered and listed as the reason to the cardiomyopathies. To study the effect of these mutations was a challenge due the difficulty to accesses cardiac cells. In 2007, the technique of reprogramming somatic cells into pluripotent stem cells was discovered. The fact that the pluripotent stem cells are capable of differentiating into cardiomyocytes opened the opportunity to study these cells from individuals with genetic mutations. This thesis aimed to create a cellular model to study Hypertrophic Cardiomyopathy caused by genetic mutations. Initially we established a cell reprogramming protocol to establish induced stem cells lines from a patient with mutation in MYH7 gene. Having characterized the cells, they were differentiated into cardiomyocytes using an adapted protocol from direct differentiation protocols. Cardiomyocytes generated showed molecular and functional characteristics similar to human primary cardiomyocytes and were visualized by means of transmission electron microscopy. The patient\'s cardiomyocytes had a large proportion of disorganized sarcomeres compared to cardiomyocytes from healthy individuals. In conclusion, the cell model developed suggests that it is possible to study the effect of genetic mutation in Hypertrophic Cardiomyopathy using induced pluripotent stem cells derived cardiomyocytes.